Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
暂无分享,去创建一个
M. Mann | K. Garcia | J. Sidney | A. Sette | I. Pollack | S. Mueller | H. Okada | R. Rajalingam | G. Kohanbash | A. Carcaboso | Xinbo Yang | Yafei Hou | Yi Lin | Diego A. Carrera | P. Watchmaker | Zinal S Chheda | K. Okada | S. Shrivastav | Shuming Liu | Naznin Jahan | M. Pecoraro | Pavlina Chuntova | Kira M. Downey | Diego A Carrera | Chetana Lagisetti
[1] Michael Platten,et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy , 2017, Oncoimmunology.
[2] D. Ellison,et al. Molecular pathology of paediatric central nervous system tumours , 2017, The Journal of pathology.
[3] J. Barnholtz-Sloan,et al. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010 , 2016, Neuro-oncology.
[4] S. Lageman,et al. National Institute of Neurological Disorders and Stroke , 2017 .
[5] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[6] Arie Perry,et al. Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.
[7] Liang Cheng,et al. The 2016 World Health Organization classification of tumors of the urinary system and male genital organs: implications for the urologist , 2016 .
[8] F. Furnari,et al. Epidermal growth factor receptor targeting and challenges in glioblastoma. , 2016, Neuro-oncology.
[9] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[10] N. Ahmed,et al. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. , 2016, Biochemical Society transactions.
[11] W. Wels,et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival , 2016, Oncoimmunology.
[12] J. Gartner,et al. Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.
[13] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[14] Na Li,et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.
[15] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[16] Simon C Watkins,et al. STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[17] Chris Jones,et al. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.
[18] S. Stevanović,et al. A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.
[19] Mark M. Davis,et al. Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.
[20] O. Becher,et al. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology , 2014, Pediatric Research.
[21] C. June,et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts , 2013, Journal of Immunotherapy for Cancer.
[22] Bent K Jakobsen,et al. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.
[23] P. Wen,et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma , 2013, Expert review of vaccines.
[24] R. Kebudi,et al. Management of Diffuse Pontine Gliomas in Children: Recent Developments , 2013, Pediatric Drugs.
[25] Tongguang Wang,et al. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.
[26] Clemencia Pinilla,et al. Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.
[27] H. Ikeda,et al. A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression , 2012, Molecular therapy. Nucleic acids.
[28] B. Jakobsen,et al. Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies , 2012, European journal of immunology.
[29] David T. W. Jones,et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.
[30] R. Morgan,et al. Genetic engineering with T cell receptors. , 2012, Advanced Drug Delivery Reviews.
[31] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[32] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[33] M. Merino,et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] Edward R. Kastenhuber,et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners , 2010, Cancer Immunology, Immunotherapy.
[35] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] R. Debets,et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. , 2010, Trends in molecular medicine.
[37] H. Ikeda,et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. , 2009, Cancer research.
[38] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[39] Edward R. Kastenhuber,et al. Immunotherapeutic approaches for glioma. , 2009, Critical reviews in immunology.
[40] Jian Huang,et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. , 2007, Cancer research.
[41] Andrew K. Sewell,et al. Human TCR-Binding Affinity is Governed by MHC Class Restriction1 , 2007, The Journal of Immunology.
[42] Junichi Eguchi,et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models , 2007, Journal of Translational Medicine.
[43] Jian Gang Zhang,et al. Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics , 2007, Clinical Cancer Research.
[44] I. Pollack,et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. , 2006, Cancer research.
[45] S. Steinberg,et al. Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.
[46] I. Pollack,et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. , 2005, Neoplasia.
[47] Paul Tempst,et al. Histone Deimination Antagonizes Arginine Methylation , 2004, Cell.
[48] M. A. van der Hoorn,et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. , 2003, Blood.
[49] F. Marincola,et al. Functional characterization of CTL against gp100 altered peptide ligands , 2003, Cancer Immunology, Immunotherapy.
[50] I. Pollack,et al. Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain , 2002 .
[51] I. Pollack,et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] Y. Rivière,et al. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. , 2001, Journal of immunological methods.
[53] M. Garcia-Peydró,et al. Antagonism of Direct Alloreactivity of an HLA-B27-Specific CTL Clone by Altered Peptide Ligands of Its Natural Epitope1 , 2000, The Journal of Immunology.
[54] C. Farina,et al. Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.
[55] A Sette,et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.
[56] M. Boeker,et al. Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions , 1997, Allergy.
[57] M. van de Weert,et al. Identification of oxidized methionine in peptides. , 1996, Rapid communications in mass spectrometry : RCM.
[58] C. Figdor,et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. , 1995, Cancer research.
[59] D. Wiley,et al. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Wells,et al. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.
[61] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.